Or­chard lines up mon­ey for pro­posed Lib­meldy ex­pan­sion; Har­bour touts PhI­II

Gene ther­a­py mak­er Or­chard Ther­a­peu­tics is ex­tend­ing its cash run­way in­to 2025 with new fi­nanc­ing agree­ments to bankroll its path to reg­u­la­to­ry ap­proval.

The Lon­don …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER